Literature DB >> 2808208

Interactions of meropenem with class I chromosomal beta-lactamases.

Y J Yang1, D M Livermore.   

Abstract

Most newer penicillins and cephalosporins are labile to the Class I beta-lactamases that are inducible in Pseudomonas aeruginosa. Enterobacter spp., Citrobacter spp., Serratia spp. and indole-positive Proteeae, but fail to induce enzyme synthesis below the MIC. They remain active against the inducible strains but not against mutants (termed 'stably depressed') that manufacture beta-lactamase copiously without induction. Such mutants are segregated at high frequency and may be selected during therapy, sometimes causing clinical failure. Meropenem induced Class I enzymes weakly below the MIC in Ps. aeruginosa, Ent. cloacae, C. freundii, Ser. marcescens, Morganella morganii and Pr. vulgaris. Nonetheless it remained equally active against inducible strains and their derepressed mutants, and was no more active against laboratory-derived beta-lactamase basal mutants. It did not select derepressed mutants from beta-lactamase-inducible populations. These data suggested great stability to Class I beta-lactamases, and this deduction was confirmed by direct assays with purified beta-lactamases. Initial hydrolysis rates ranged from 0.9-10.0 drug molecules hydrolysed/enzyme molecule/minute but these values declined by 80-90% before 5% of the antibiotic had been hydrolysed, indicating that the carbapenem could deactivate the enzymes. Deactivation was reversible, full activity being restored once the meropenem was removed. These results suggest that meropenem, like imipenem and various experimental penems, may overcome the resistance problems presented by Class I beta-lactamases.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2808208     DOI: 10.1093/jac/24.suppl_a.207

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  18 in total

1.  Interplay of impermeability and chromosomal beta-lactamase activity in imipenem-resistant Pseudomonas aeruginosa.

Authors:  D M Livermore
Journal:  Antimicrob Agents Chemother       Date:  1992-09       Impact factor: 5.191

2.  In vitro activity of a catechol-substituted cephalosporin, GR69153.

Authors:  R Wise; J M Andrews; J P Ashby; D Thornber
Journal:  Antimicrob Agents Chemother       Date:  1991-02       Impact factor: 5.191

3.  Emergence of resistance to beta-lactam agents in Pseudomonas aeruginosa with group I beta-lactamases in Spain.

Authors:  K Colom; A Fdz-Aranguiz; E Suinaga; R Cisterna
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1995-11       Impact factor: 3.267

4.  Biochemical characterization of a beta-lactamase that hydrolyzes penems and carbapenems from two Serratia marcescens isolates.

Authors:  Y J Yang; P J Wu; D M Livermore
Journal:  Antimicrob Agents Chemother       Date:  1990-05       Impact factor: 5.191

5.  Imipenem and meropenem: Comparison of in vitro activity, pharmacokinetics, clinical trials and adverse effects.

Authors:  G G Zhanel; A E Simor; L Vercaigne; L Mandell
Journal:  Can J Infect Dis       Date:  1998-07

6.  Activity of ertapenem (MK-0826) versus Enterobacteriaceae with potent beta-lactamases.

Authors:  D M Livermore; K J Oakton; M W Carter; M Warner
Journal:  Antimicrob Agents Chemother       Date:  2001-10       Impact factor: 5.191

7.  Role of cephalosporinase in carbapenem resistance of clinical isolates of Pseudomonas aeruginosa.

Authors:  X Y Zhou; M D Kitzis; L Gutmann
Journal:  Antimicrob Agents Chemother       Date:  1993-06       Impact factor: 5.191

Review 8.  Meropenem clinical pharmacokinetics.

Authors:  J W Mouton; J N van den Anker
Journal:  Clin Pharmacokinet       Date:  1995-04       Impact factor: 6.447

9.  Doripenem versus Pseudomonas aeruginosa in vitro: activity against characterized isolates, mutants, and transconjugants and resistance selection potential.

Authors:  Shazad Mushtaq; Yigong Ge; David M Livermore
Journal:  Antimicrob Agents Chemother       Date:  2004-08       Impact factor: 5.191

10.  Imipenem- and meropenem-resistant mutants of Enterobacter cloacae and Proteus rettgeri lack porins.

Authors:  A Raimondi; A Traverso; H Nikaido
Journal:  Antimicrob Agents Chemother       Date:  1991-06       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.